Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

vasopharm GMBH

www.vasopharm.com

Latest From Sanwa Kagaku Kenkyusho Co. Ltd.

Oncology Dominates Japan Approvals, Though Overall Tally Is Lower

Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.

Approvals Regulation

ANALYSIS: Unravelling Japan’s Biosimilar Opportunities

MP Advisors sees a cumulative biosimilars opportunity of around JPY400 billion ($3.31 billion) in Japan over the next five years as some big-selling biologics come off local patent. But the next few years will provide further clarity on the value of different strategies for complex monoclonal antibody (mAb) biosimilar penetration in the country.

BioPharmaceutical Japan

Chuikyo Releases New Round Of Price Listings In Japan

BMS’ Orencia, Sanofi’s Lyxumia, Chugai’s Perjeta and others are now cleared for the market after receiving National Health Insurance price listings.

BioPharmaceutical Japan

NAS in 2012: launch tally is century's best

R&D in the international pharmaceutical industry appears in ruder health than some might think. In 2012, the number of new active substances (NAS) launched in their first markets worldwide hit 39 – the highest tally since 2000, new research from Scrip Intelligence has found.

Gastrointestinal Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • vasopharm Biotech GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • vasopharm GMBH
  • Senior Management
  • Christian Wandersee, CEO
    Frank Tegtmeier, PhD, CSO
  • Contact Info
  • vasopharm GMBH
    Phone: (49) 931 35 90 99-0
    Friedrich-Bergius-Ring 15
    Wuerzburg, 97076
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register